United States · FDA National Drug Code directory
Adalimumab-ryvk
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 51759-361_ed0b2de6-71a4-439f-a464-f7383cf5dd4e
- Product NDC
- 51759-361
- Form
- KIT
- Composition / generic term
- adalimumab-ryvk
- Labeler
- Teva Pharmaceuticals USA, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20250701
- Source listing expiry
- 20261231
Source-listed ingredients
Separate ingredient quantities are not available in this snapshot. Any composition term above is preserved as source text.
These values do not establish equivalence or a dose recommendation.
Packages
- 1 KIT in 1 CARTON (51759-361-17) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .8 mL in 1 SYRINGE * .4 mL in 1 POUCH · 51759-361-17
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →